🚀 VC round data is live in beta, check it out!
Agomab Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Agomab Therapeutics and similar public comparables like Nika Pharmaceuticals, Akums Drugs and Pharma, Bright Minds Biosciences, Polaris Group and more.
Agomab Therapeutics Overview
About Agomab Therapeutics
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
Founded
2017
HQ
Employees
80
Website
Sectors
Financials (FY)
EV
$637M
Agomab Therapeutics Financials
Agomab Therapeutics reported last fiscal year revenue of — and negative EBITDA of ($53M).
In the same fiscal year, Agomab Therapeutics generated ($53M) in EBITDA losses and had net loss of ($53M).
Agomab Therapeutics P&L
In the most recent fiscal year, Agomab Therapeutics reported revenue of — and EBITDA of ($53M).
Agomab Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($53M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($53M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Agomab Therapeutics Stock Performance
Agomab Therapeutics has current market cap of $789M, and enterprise value of $637M.
Market Cap Evolution
Agomab Therapeutics' stock price is $16.19.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $637M | $789M | — | XXX | XXX | XXX | $-1.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAgomab Therapeutics Valuation Multiples
Agomab Therapeutics trades at (12.0x) EV/EBITDA.
Agomab Therapeutics Financial Valuation Multiples
As of March 28, 2026, Agomab Therapeutics has market cap of $789M and EV of $637M.
Equity research analysts estimate Agomab Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Agomab Therapeutics has a P/E ratio of (14.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $789M | XXX | $789M | XXX | XXX | XXX |
| EV (current) | $637M | XXX | $637M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (12.0x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (11.5x) | XXX | XXX | XXX |
| P/E | — | XXX | (14.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (11.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Agomab Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Agomab Therapeutics Margins & Growth Rates
Agomab Therapeutics' revenue in the last fiscal year grew by —.
Agomab Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 286% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Agomab Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nika Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Akums Drugs and Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Bright Minds Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Polaris Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Annexon | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Agomab Therapeutics M&A Activity
Agomab Therapeutics acquired XXX companies to date.
Last acquisition by Agomab Therapeutics was on XXXXXXXX, XXXXX. Agomab Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Agomab Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAgomab Therapeutics Investment Activity
Agomab Therapeutics invested in XXX companies to date.
Agomab Therapeutics made its latest investment on XXXXXXXX, XXXXX. Agomab Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Agomab Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Agomab Therapeutics
| When was Agomab Therapeutics founded? | Agomab Therapeutics was founded in 2017. |
| Where is Agomab Therapeutics headquartered? | Agomab Therapeutics is headquartered in Belgium. |
| How many employees does Agomab Therapeutics have? | As of today, Agomab Therapeutics has over 80 employees. |
| Is Agomab Therapeutics publicly listed? | Yes, Agomab Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Agomab Therapeutics? | Agomab Therapeutics trades under AGMB ticker. |
| When did Agomab Therapeutics go public? | Agomab Therapeutics went public in 2026. |
| Who are competitors of Agomab Therapeutics? | Agomab Therapeutics main competitors are Nika Pharmaceuticals, Akums Drugs and Pharma, Bright Minds Biosciences, Polaris Group. |
| What is the current market cap of Agomab Therapeutics? | Agomab Therapeutics' current market cap is $789M. |
| Is Agomab Therapeutics profitable? | No, Agomab Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.